For research and educational purposes only. Not medical advice.

Articles

Research articles on peptides, GLP-1s, SARMs, fitness, sleep, recovery, and longevity, written in plain English with primary citations.

Public articles

• What happens to your weight when you stop a GLP-1 (GLP-1; 5 min read). You hit your goal, or your prescription lapses, or you just want off the needle, and the obvious question follows: will the weight stay off? The honest answer from the trials that deliberately stopped the drug is that most people regain a large share of what they lost. Here is what the semaglutide and tirzepatide withdrawal studies found, why it happens, and what the data do and do not tell you about keeping it off.
• GLP-1 nausea and side effects: what actually helps (GLP-1; 8 min read). Nausea is the side effect that fills the GLP-1 forums, but it is rarely the whole story. Here is the plain version: why the gut stuff happens, what genuinely helps the nausea, where sulfur burps, diarrhea, constipation, fatigue, and injection-site reactions fit, and an honest answer to the question everyone asks, couldn't handle semaglutide, should I try tirzepatide?
• BPC-157 oral vs injectable: does the capsule work? (Peptides; 8 min read). BPC-157 is sold as both subcutaneous vials and oral capsules, and the marketing treats them as the same product. They are not. This separates what the rodent literature actually supports for each route, explains why a peptide that survives stomach acid still may not reach your bloodstream, and gives an honest read on choosing a route for a compound with no human pharmacokinetic data at all.
• Retatrutide weight loss timeline: what the trials show (GLP-1; 6 min read). You have heard the headline number on retatrutide: about a quarter of body weight in the big trial. The question people ask next is when. Here is the honest trajectory from the actual studies, stage by stage: the slow start while the dose climbs, the midpoint, the 48-week mark where the average was still falling, and the longer Phase 3 arc out past two years. These are trial averages, not a schedule you can bank on for yourself.
• Retatrutide side effects: what the trials actually found (GLP-1; 7 min read). If you are weighing retatrutide, the side-effect question is the one that actually keeps people up at night. Here is the honest version from the trials rather than the forums: which effects showed up, how often, how rough they tended to be, when they hit, and how many people quit because of them. Then a straight word on why the stuff you read online is real experience but not measured data.
• The melanocortin system: MC4R, hunger, and its drugs (Peptides; 7 min read). One small receptor family, melanocortin 1 through 5, sits behind skin color, the stress-hormone axis, and appetite, and is the target of three very different approved drugs. This is the whole family on one page: what each receptor does, which signal turns it on, and why a drug aimed at hunger can also tan your skin.
• How much weight can you actually lose on retatrutide (GLP-1; 6 min read). Retatrutide is the triple-hormone obesity drug everyone is watching, and the reason is the weight-loss number. In its trials it has produced the largest average loss of any obesity drug studied so far. Here is what the actual trial figures are, how they stack up against Ozempic and Zepbound, and why a trial average is not a number you can bank on for yourself.
• Sulfur burps on GLP-1s: what to eat and what to cut (GLP-1; 5 min read). Rotten-egg burps are one of the most talked-about GLP-1 side effects, and they live almost entirely in food territory. Here is why a slowed-down stomach plus sulfur-heavy, fatty meals makes the smell, the foods worth easing off for a day or two, and the simple levers (smaller meals, real chewing, a walk after eating) that usually settle it.
• Oral peptide bioavailability: which peptides absorb (Peptides; 7 min read). Most peptides make terrible pills. The gut digests them and the intestinal lining blocks them, so oral bioavailability is usually under 1 to 2 percent. A short list of drugs gets around that, each with a different trick. Here is the route, the real absorption numbers from the labels and the PK literature, and what 'best oral peptide bioavailability' actually means.
• What food noise is, and why semaglutide quiets it (GLP-1; 6 min read). Food noise is the constant mental chatter about food that does not switch off: the snack you keep circling back to, the running tally of what you ate. A lot of people on semaglutide say it just goes quiet. Here is the plain version of what food noise is, why a weight and diabetes drug turns the volume down, and what that does and does not mean.
• Retatrutide and food noise: what the evidence says (GLP-1; 6 min read). People on retatrutide keep saying the same thing: the constant mental chatter about food just goes quiet. Here is the honest version of why that happens, why most of the hard data is on semaglutide rather than retatrutide, and why the fact that retatrutide is still an investigational drug matters before you read too much into the quiet.
• How setmelanotide works: the MC4R hunger switch (Peptides; 6 min read). Setmelanotide (Imcivree) is the rare-obesity drug that works by replacing a missing brain signal. This is the plain-language mechanism: how the leptin-to-MC4R appetite pathway runs, where single genes break it, what setmelanotide switches back on, and why the same action shows up as darker skin.
• CJC-1295 + ipamorelin vs HGH: what the data shows (Peptides; 8 min read). Growth-hormone peptides like CJC-1295 and ipamorelin get marketed as a softer, legal alternative to injectable HGH. They are not the same thing. One is an FDA-approved hormone with a decades-long trial record; the other two are unapproved research peptides with thin human data. This walks the mechanism, the actual evidence, what the bloodwork measures, and the legal and anti-doping reality.
• Beyond Ozempic: how GLP-1s lit the peptide boom (GLP-1; 12 min read). Semaglutide and tirzepatide turned a pharmacology word, 'peptide', into a consumer category. The GLP-1 drugs earned the attention with hard trial numbers. The compounds being marketed in their slipstream, growth-hormone secretagogues like CJC-1295 plus ipamorelin and a long tail of gray-market metabolic peptides, mostly have not. This separates the two and explains the compounding fight underneath.
• Lead in Protein Powder: 2025 Consumer Reports Test (Fitness; 9 min read). Consumer Reports retested 23 popular protein powders and shakes in October 2025 and found more than two thirds carried more lead per serving than CR's 0.5 microgram daily reference. Plant-based ran nine times the dairy average. The Clean Label Project's separate January 2025 whitepaper added the counterintuitive organic-worse and chocolate-worse findings, but the two studies do not agree on flavor effects. California SB 1033 would force lot-level disclosure starting January 2028.
• Peptide dosing: mg, mcg, units, and the math that works (Peptides; 7 min read). Milligrams, micrograms, and "units" describe three different things, and new users keep treating them as interchangeable. A milligram is mass. A microgram is one thousandth of that mass. A unit on an insulin syringe is a volume convention borrowed from U-100 insulin. The arithmetic that ties them together depends on a concentration the user picked at reconstitution. This is the dosing-literacy explainer the catalog needs, with the math in plain numbers and the harm pattern grounded in FDA alerts.
• Vetting peptide providers: who to trust, who to skip (Research Gaps; 12 min read). Peptide marketing has outrun peptide regulation. Most consumer-facing peptide claims travel through wellness telehealth, social-media influencers, and research-supply marketplaces that look medical but sit outside the FDA approval system. This piece walks the provider landscape: who can actually prescribe a peptide for human use in the United States, how 503A and 503B pharmacies fit into the supply chain, what research-use-only really means as a legal posture, and the red flags that signal a provider has slid from clinical practice into product marketing.
• Combination therapies and integrated peptide programs: which stacks have evidence, which have only program design (Peptides; 12 min read). Integrative clinics now bundle peptides with hormone replacement, IV nutrient infusions, resistance training, and lifestyle coaching. The evidence base across those layers is wildly uneven, and the article breaks the stack into three honest buckets so a reader can tell controlled-trial support from clinic-program convention.
• Retatrutide vs Tirzepatide: trials and field reports (GLP-1; 11 min read). Retatrutide is Eli Lilly's investigational triple agonist (GIP, GLP-1, glucagon). Tirzepatide (Mounjaro, Zepbound) is the dual GIP/GLP-1 agonist already on label. No head-to-head trial exists. This walks the trial numbers side by side and layers in what users consistently report, with weaker sources flagged inline.
• Peptides in 2026: the biohacker's no-BS field guide (Peptides; 15 min read). A blunt roundup of where the 2026 peptide market actually sits across healing, fat loss, and longevity. Names the compounds that carry real human trial evidence (a small group of GLP-1s), the ones with a real preclinical signal and almost no human trials (BPC-157, TB-500, GHK-Cu), and the ones that are informed bets on mechanism (rapamycin, NMN, NR, MOTS-c, senolytics). Then walks the four risk vectors that decide whether any peptide protocol survives contact with a real vial.
• KLOW Stack KPV, LL-37, Oxytocin, and Wolverine: what the evidence actually supports (Stacks; 12 min read). KLOW is a community shorthand for a four-part blend of KPV, LL-37, Oxytocin, and the Wolverine pair (BPC-157 plus TB-500). It is not an FDA-approved protocol, has no controlled human trial as a stack, and most of its individual components also lack large human efficacy data. This piece works through what each constituent does, where the evidence sits, and where the stack story outruns the data.
• GLOW Stack GHK-Cu, BPC-157, and TB-500: what the evidence actually supports (Stacks; 11 min read). GLOW is community shorthand for a three-part blend of GHK-Cu, BPC-157, and TB-500 marketed for skin quality, collagen, and recovery. It is not an FDA-approved protocol and has no controlled human trial as a stack. This piece walks through each component, where the evidence is real, and where the marketing leans on extrapolation from topical or animal data.
• The wild west of peptides: hype, safety, and the gaps the marketing will not show you (Research Gaps; 12 min read). Peptide demand outran the trial base because social-media marketing got there first. The real-world risk is not philosophical. It is sourcing, identity, purity, endotoxin, and dose drift on vials that were never built to be drugs. This is the safety-and-evidence companion to the in-demand-peptides market watch.
• Will your body stop making peptides if you inject them? (Research Gaps; 12 min read). Walks the question of whether injecting peptides trains the body to stop producing them. BPC-157, TB-500, and GHK-Cu do not have a published feedback loop for exogenous administration to suppress. Pituitary releasing-factor analogs (CJC-1295, ipamorelin, tesamorelin) keep the axis responsive across the studied dosing windows and revert after discontinuation. GLP-1 receptor agonists are external mimics where stopping reverts hunger and metabolic signaling, not native GLP-1 production. The long-term access question is the more durable worry.
• Most in-demand peptides of 2026: what's hyped, what works, what hurts you (Peptides; 11 min read). Integrative-clinic and med-spa demand keeps clustering on six names: BPC-157, CJC-1295 plus ipamorelin, semax, selank, TB-500, and melanotan II. Here is what the human evidence actually shows, where marketing outruns the trials, what each one is banned for in tested sport, and which one has documented harm.
• GLP-1 receptor agonists beyond obesity and diabetes: HFpEF, PAD, and PCOS (GLP-1; 10 min read). GLP-1 receptor agonists have moved past obesity and type 2 diabetes into a string of new indications. STEP-HFpEF, STEP-HFpEF DM, and the tirzepatide SUMMIT trial built the heart failure with preserved ejection fraction case. STRIDE landed the first Phase 3 readout in peripheral artery disease with type 2 diabetes. PCOS evidence is meta-analytic, not registrational. This piece walks each indication, the trial that generated the signal, and what regulatory posture looks like at publication.
• Wolverine Stack BPC-157 and TB-500: what the evidence actually supports (Peptides; 10 min read). The Wolverine Stack is community shorthand for pairing BPC-157 with TB-500, usually for injury recovery. The evidence is mostly preclinical for BPC-157 and mostly extrapolated from full-length thymosin beta-4 for TB-500, so the stack is not an FDA-approved protocol or a validated clinical treatment.
• Orforglipron and the rise of oral GLP-1s (GLP-1; 9 min read). Orforglipron is an investigational once-daily oral non-peptide GLP-1 receptor agonist. The ATTAIN-1 obesity Phase 3 trial reported about 11.2 percent mean weight loss at 36 mg over 72 weeks. The ATTAIN-MAINTAIN Phase 3b switch trial (Aronne 2026 Nature Medicine, n=376, 52 weeks) reported that adults who switched from injectable tirzepatide or semaglutide to oral orforglipron maintained about 74.7 to 79.3 percent of their prior weight loss versus 37.6 to 49.2 percent on placebo. This piece walks the pharmacology, the trial readouts, and where oral fits next to weekly injectables.
• Wegovy HD and CagriSema, the next bar for injectable GLP-1s (GLP-1; 9 min read). The FDA approved Wegovy HD (semaglutide 7.2 mg) on March 19, 2026, after the STEP UP Phase 3b trial showed about 20.7 percent mean body weight reduction at 72 weeks in adherent participants. The cagrilintide plus semaglutide combination CagriSema reported 20.4 percent at 68 weeks in REDEFINE-1 and 13.7 percent in REDEFINE-2 (adults with type 2 diabetes). This piece walks what changed mechanistically, what each trial actually measured, and where the practical caveats sit.
• PT-141 (bremelanotide), the melanocortin pathway, and what Vyleesi was actually approved for (Peptides; 8 min read). Bremelanotide (Vyleesi) is an FDA-approved subcutaneous melanocortin receptor agonist for premenopausal women with acquired, generalized hypoactive sexual desire disorder. The published trial program (RECONNECT) anchored the label, but the approved indication, dose, and warnings are narrower than community framing suggests. This piece walks the pivotal data, the mechanism, the safety profile, and what falls outside the label.
• MOTS-c, the mitochondrial-derived peptide, and what the rodent metabolic literature does and does not show (Peptides; 7 min read). MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S rRNA gene. The foundational rodent metabolic-homeostasis work (Lee 2015, Cell Metabolism) is reproducible and well-cited, and the broader mitochondrial-derived peptide (MDP) field has grown around it. Human evidence is still limited to observational circulating-level descriptions; no human pharmacokinetic, pharmacodynamic, or outcome study of administered MOTS-c has read out.
• Setmelanotide (Imcivree), the MC4R agonist for genetic obesity, and what its FDA label actually covers (Peptides; 8 min read). Setmelanotide (Imcivree) is a selective MC4R agonist approved by the FDA for chronic weight management in patients with rare genetic obesity disorders, including POMC, PCSK1, and LEPR deficiency, and Bardet-Biedl syndrome. The pivotal evidence is small but precise: outcomes in identified single-gene populations rather than population-level obesity. This piece walks the mechanism, the indication-by-indication label, the trial results, and the boundary between approved use and broader MC4R framing.
• Kisspeptin-10, the KISS1R-GnRH neuron link, and what the published human fertility literature actually uses (Peptides; 8 min read). Kisspeptin is the upstream gatekeeper of the hypothalamic-pituitary-gonadal axis. The published human trial literature is real and growing, but most of it uses kisspeptin-54, not the research-vial kisspeptin-10 that the community calls KP-10. This piece walks the KISS1R biology, the trial program in functional hypothalamic amenorrhea and IVF, and the gap between trial peptide and research-vial peptide.
• AOD-9604, the growth-hormone fragment 177-191, and why the Phase 2 obesity readouts underdelivered (Peptides; 7 min read). AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone (residues 177-191) with an added N-terminal tyrosine, retaining the native Cys182-Cys189 disulfide bridge. Developed by Metabolic Pharmaceuticals as a fat-loss therapy, the preclinical lipolytic story in adipocytes is well-cited, but the human Phase 2b program in obese adults produced only a small placebo-adjusted weight difference that fell well short of the regulatory bar. The molecule remains a research-vial compound, not an FDA-approved obesity therapy.
• Retatrutide: the triple agonist behind 28.7 percent weight loss in TRIUMPH-4 (GLP-1; 8 min read). Retatrutide is Eli Lilly's investigational once-weekly injectable that activates three incretin and metabolic receptors at once: GIP, GLP-1, and glucagon. The Phase 2 trial reported mean weight reductions of about 24 percent at 12 mg over 48 weeks, and the first Phase 3 readout (TRIUMPH-4, December 2025) reported up to 28.7 percent at 68 weeks alongside improvements in knee pain and several cardiometabolic markers. This piece walks the pharmacology, the trial data, what the comparison to earlier GLP-1 drugs actually shows, and what the rest of the TRIUMPH program may add.
• FDA peptide compounding 2026: the no-BS breakdown on BPC-157, TB-500, and the rest (Peptides; 10 min read). BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon did not get FDA-approved in April 2026. They came off an interim enforcement list and now face a July PCAC review. This is the blunt version of what changed, what did not, and why the evidence argument is more complicated than either the hype or the doomer posts admit.
• What standard blood panels actually tell you, and what they miss (Research Gaps; 10 min read). A widely shared Reddit-style sign says "standard blood panels are designed to keep you out of the ER, not tell you why you feel like garbage." The framing is overstated but the underlying complaint is real. Standard panels (CBC, BMP/CMP, lipid panel) were built to screen for the acute or organ-level problems a clinician cannot afford to miss. They were not built to explain why a person inside reference range still feels exhausted, foggy, or off. This piece walks what standard panels actually screen for, why reference ranges are statistical bands rather than wellness verdicts, the five most common gaps where standard panels miss symptom-relevant pathology (subclinical hypothyroidism, low ferritin without anemia, vitamin D and B12 insufficiency, early insulin resistance, and low-normal sex hormones), and the targeted second-tier labs that close those gaps.
• GLP-1 drugs and alcohol cravings: what the trial evidence shows (GLP-1; 10 min read). GLP-1 receptor agonists like semaglutide, tirzepatide, and exenatide are showing a consistent but still early signal that they reduce alcohol craving and consumption. A 2025 phase 2 trial in JAMA Psychiatry reported lower craving and lab-measured drinking on low-dose semaglutide. A 2022 exenatide trial missed its overall primary endpoint but reduced brain reward-cue reactivity and helped a higher-BMI subgroup. Real-world data and a 2025 meta-analysis line up directionally. None of these drugs are FDA-approved for alcohol use disorder. This article walks the trials, the mechanism, and the gaps the evidence does not yet resolve.
• GLP-1 cardiovascular outcomes: SELECT, STEP-HFpEF, FLOW, and what changed in 2024 (GLP-1; 9 min read). GLP-1 receptor agonists started as glycemic drugs and matured into cardio-renal-metabolic drugs. SELECT brought a 20 percent reduction in major cardiovascular events to non-diabetic patients with obesity. STEP-HFpEF showed symptomatic and weight benefit in obesity-driven HFpEF. FLOW reported a 24 percent reduction in major kidney outcomes in type 2 diabetes plus chronic kidney disease. This piece walks the trial designs, the effect sizes, the magnitudes left unanswered, and the FDA label changes that followed.
• Tirzepatide for obstructive sleep apnea: what SURMOUNT-OSA actually showed (GLP-1; 8 min read). Obstructive sleep apnea is the most common sleep-disordered breathing condition, and obesity is its strongest modifiable risk factor. The SURMOUNT-OSA trials tested whether tirzepatide could meaningfully reduce apnea-hypopnea index (AHI) in adults with moderate-to-severe OSA and obesity, both with and without concurrent positive airway pressure therapy. This piece walks the trial design, the magnitude of AHI reduction, the cardiometabolic secondary endpoints, the FDA label change in December 2024, and the open question of how the AHI improvement relates to long-term clinical outcomes.
• Creatine monohydrate: 30 years of evidence and the cognitive question (Fitness; 9 min read). Creatine monohydrate is among the most extensively studied sports-nutrition supplements, with the 2017 ISSN position stand summarizing its evidence base. Decades of randomized trials and meta-analyses converge on a small-to-moderate strength and lean-mass benefit at 3 to 5 grams per day, with a clean safety profile in healthy adults. The cognitive literature is newer, more heterogeneous, and emerging from sleep-deprivation and aging cohorts. This piece walks the position-stand evidence, the strength and hypertrophy meta-analyses, the cognitive trials, the kidney-and-hair safety questions, and the practical dosing protocols.
• Omega-3 and cardiovascular outcomes: REDUCE-IT, STRENGTH, VITAL, and the EPA-versus-mixture question (Longevity; 9 min read). Omega-3 supplementation has more conflicting trial data than almost any other widely sold supplement. REDUCE-IT showed a 25 percent relative risk reduction in major cardiovascular events with high-dose icosapent ethyl in statin-treated patients with elevated triglycerides. STRENGTH was neutral with a different EPA plus DHA carboxylic acid formulation. VITAL was neutral on primary cardiovascular outcomes with low-dose marine n-3 in a primary-prevention population. This piece walks the trial designs, the formulation differences, the placebo controversy, and what current clinical guidance actually says.
• Vitamin D supplementation: VITAL, fractures, and the deficiency-versus-supplementation distinction (Longevity; 8 min read). Vitamin D supplementation has been one of the most-purchased and most-debated supplements of the last 20 years. The VITAL trial (25,871 adults, 5+ years follow-up) is now the largest RCT of vitamin D supplementation in generally healthy adults and was negative on its primary cardiovascular and cancer endpoints. The companion fracture analysis (LeBoff 2022) was negative on total, nonvertebral, and hip fractures. This piece walks the difference between treating documented deficiency and routine supplementation in replete adults, the autoimmune disease finding, and what the trial cannot rule out.
• Zone 2 training: mitochondrial efficiency, the lactate threshold, and what the literature actually supports (Fitness; 8 min read). Zone 2 has become a popular endurance prescription, advertised as the workout that drives mitochondrial density, improves fat oxidation, and protects metabolic health. The underlying physiology (lactate kinetics, mitochondrial biogenesis, polarized training distribution) is well-grounded. The popular dosing prescriptions are looser than the literature would support. This piece walks the lactate threshold framework, the polarized-training trial record, the mitochondrial biology, and what the field does and does not yet know about specific dose-response.
• Continuous glucose monitors in non-diabetic users: signal versus noise (Research Gaps; 8 min read). The FDA cleared the first over-the-counter continuous glucose monitors for non-diabetic and non-insulin-using adults in 2024 (Dexcom Stelo, Abbott Lingo, Abbott Libre Rio). The marketing has rapidly outpaced the evidence base. CGMs reliably show postprandial glucose excursions and intra-individual variability, but in non-diabetic adults the trial-level data on whether CGM-driven dietary changes improve hard outcomes is thin. This piece walks the device technology, the FDA clearances, the published RCT and observational evidence, the inter-individual variability problem, and what a CGM in a non-diabetic user can and cannot reliably tell you.
• Time-restricted eating: TREAT, TIME, and the calorie-deficit confound (Fitness; 8 min read). Time-restricted eating (a form of intermittent fasting that limits the daily eating window without an explicit calorie target) has been one of the most popular nutritional interventions of the last decade. The trial record is more deflating than the popular discussion suggests. TREAT (Lowe 2020) and the TIME trial (Liu 2022 NEJM) both showed that time-restricted eating did not produce greater weight loss than non-restricted-window controls or daily calorie restriction at matched intake. This piece walks the trial designs, the metabolic-flexibility hypothesis, the practical subgroup where TRE may help, and what the literature actually shows.
• Heart rate variability: what the literature supports and where it overpromises (Recovery; 8 min read). Heart rate variability (HRV) has become a staple of consumer wearables, marketed as a quantitative readout of recovery, stress, and overall fitness. The underlying autonomic-cardiac physiology is real, the elite-endurance training literature has a careful track record using HRV-guided dosing, and prognostic data tie low resting HRV to cardiovascular mortality. The consumer marketing extends well beyond what the trial record supports. This piece walks the time-domain and frequency-domain metrics, the trial evidence for HRV-guided training, the prognostic literature, the wrist-versus-chest measurement issue, and what HRV in a consumer wearable can and cannot reliably tell you.
• Magnesium supplementation: where the RCT evidence actually is, claim by claim (Recovery; 8 min read). Magnesium is a routinely deficient mineral in modern Western diets, an essential cofactor in over 300 enzyme reactions, and a popular supplement marketed for sleep, cramps, anxiety, and cardiometabolic health. The trial record is mixed and claim-specific. Some uses (severe deficiency, eclampsia, certain arrhythmia contexts) are well-established; others (sleep onset, leg cramps, generalized anxiety) rest on small or low-quality trials. This piece walks the dietary intake gap, the form-specific bioavailability differences, the published RCT evidence claim by claim, and the safety profile.
• Reconstitution math for GLP-1 self-titration: why dose calculators understate the risk that actually matters (GLP-1; 7 min read). GLP-1 self-titration is described as arithmetic. The arithmetic is the easy part. The dangerous part is the chain of unit conversions, syringe-rounding behavior, and titration-ladder timing that compounds over weeks. Here is the working physiology, the published label arithmetic, and the error modes a calculator does not catch.
• The peptide and gut-barrier axis: enteric coatings, KPV, larazotide, and what oral peptides actually do in the small intestine (Peptides; 6 min read). Most peptides do not survive the stomach. The ones that do still have to cross the gut barrier, the brush border, the mucus layer, and the tight-junction protein lattice. The published gut-barrier literature is technical but specific, and it explains why some oral peptides have a real human pharmacology and most do not.
• Body recomposition vs. weight loss: why DXA tells a different story than the bathroom scale, and what trial endpoints actually measure (Fitness; 6 min read). The scale tracks total mass. DXA tracks fat mass, lean mass, and bone mineral content separately. The trial literature reports both, and the two often disagree about whether an intervention is working. Here is what each measurement reflects, where the disagreement comes from, and what the published recomposition literature actually supports.
• Peptide bioavailability primer: why route matters more than dose for half of these compounds, and what the published PK literature actually shows (Peptides; 6 min read). Bioavailability is the percentage of an administered dose that reaches systemic circulation in active form. For peptides, the answer depends mostly on the route. Subcutaneous, intramuscular, intranasal, oral, and buccal each deliver different fractions of the same molecule. Here is the route-by-route picture from approved labels and published PK studies.
• Reading published evidence without the medical degree: tiers, p-values, effect sizes, and how to spot a thin study (Research Gaps; 14 min read). Most peptide and GLP-1 discussions cite published research without engaging the actual mechanics of how that research is built. The mechanics are not arcane. Here is the working evidence pyramid, what p-values do and do not say, why effect size beats statistical significance, and the diagnostic questions that separate a load-bearing study from a thin one.
• Why GLP-1 weight loss plateaus, and what the trials actually show (GLP-1; 4 min read). GLP-1 agonists rarely produce a smooth, monotonic weight curve. The plateau most users hit is biological, not motivational. This piece covers the receptor and energy-balance story behind it, the named trial nadirs, the adaptive-thermogenesis literature, the dose-response and multi-receptor strategies that delay the bend, and what the published evidence actually supports for breaking past it.
• BPC-157: what the evidence actually shows (Peptides; 8 min read). BPC-157 is widely used and almost entirely uncharacterized in humans. This maps the rodent literature, the missing human trial program, the FDA and WADA posture, and the identity problem with what is actually in the vials, then says what would move the evidence.
• Peptide storage and stability, the practical, evidence-grounded version (Peptides; 6 min read). Reconstitution diluent, light exposure, freeze-thaw cycles, and lyophilized vs. liquid stability windows. The science underneath the practical questions, and what the published stability literature actually shows. This piece covers degradation chemistry, the named GLP-1 in-use windows, the bacteriostatic water question, light and temperature sensitivity, freeze-thaw, the cold-chain reality of compounded products, and how to read a certificate of analysis.
• SARMs and the regulatory reality: research-only labels do not change legal posture (SARMs; 8 min read). What FDA enforcement, WADA prohibition, and state-level scheduling actually mean for SARMs in 2026, why the 'research only' label that ships on most products is regulatory cosplay rather than legal cover, and what the published clinical-trial record actually says about MK-2866, LGD-4033, and RAD-140.
• Sleep architecture and recovery: slow-wave sleep, GH pulses, and what actually moves recovery markers (Sleep; 5 min read). The interesting biology of recovery happens during a specific phase of sleep, not across the night uniformly. This piece covers the polysomnographic stages, the slow-wave-sleep / growth-hormone coupling, the named studies that established it (Van Cauter, Born), the within-night architecture changes from alcohol, caffeine, and exercise, the wearable-vs-PSG accuracy gap, and what supplements and peptides actually move (and do not move).
• Injection site rotation, lipohypertrophy, and the skin you cannot see (Peptides; 5 min read). The under-discussed reason injection site rotation matters: subcutaneous tissue remodels under repeated injection, and the remodeling changes how absorption behaves the next time. This piece covers the lipohypertrophy literature, the FITTER injection-technique consensus, the absorption-variability data, needle length and gauge, the GLP-1 site-specific PK question, and aseptic technique.
• Protein, leucine, and hypertrophy: what the per-meal threshold literature actually says (Fitness; 4 min read). The popular framing of protein and muscle-protein synthesis sits on a real research base, but the practical recommendations are often stronger than the underlying evidence supports. This piece covers the named tracer studies (Moore, Witard, Macnaughton), the leucine threshold per meal, anabolic resistance with age, the bolus-vs-frequency randomized data, total-daily-protein meta-analyses, and the GLP-1-deficit application.
• VO2max as a longevity marker: what the cohort data actually say, and what they do not (Longevity; 5 min read). VO2max correlates with all-cause mortality across large cohorts. That correlation is real, durable, and replicable, but it is not the same as a causal claim. This piece covers the named cohort findings (Mandsager 2018, Imboden 2019, Strasser 2018), the dose-response shape, the absolute VO2max numbers by age and sex, what training actually moves it, and where pharmacology has and has not been validated.
• Mitochondrial density and training: zone 2, biopsy data, and the nuance the popular framing skips (Fitness; 4 min read). The popular framing collapses mitochondrial adaptation to one zone. The biopsy and stable-isotope literature is older, denser, and more nuanced than the podcast version. This piece covers the Holloszy classical biopsy work, the PGC-1α signaling pathway, the polarization vs threshold vs zone-2 trial debate, the head-to-head HIIT vs MICT data, the mitochondrial-targeted compound landscape, and where the disagreement actually sits.
• NAD precursors, evidence snapshot: NMN, NR, niacin, and what human trials measured (Longevity; 7 min read). NAD biology is fascinating. The supplement implications are murkier than the popular framing. Here's the rundown: NAD biology and decline, the NMN vs NR biosynthesis difference, the human PK literature for both compounds, the FDA NDI dispute around NMN, the surrogate-endpoint trials that exist, and the long-term outcome trials that do not.
• GLP-1 and muscle loss: lean mass attrition during rapid weight loss, and the levers that actually work (GLP-1; 5 min read). Rapid weight loss costs lean mass. GLP-1 therapies are not unique in this, but the speed and the eating pattern they enforce make it visible faster. This piece covers the named DXA substudies (STEP, SURMOUNT, SUSTAIN), the lean-fraction comparison versus surgical and dietary loss, the protein-and-resistance-training literature, the older-adult sarcopenia question, and the open multi-receptor / amylin question.
• Women and peptide research gaps: trial representation, dose interpretation, and where the gap is closing (Research Gaps; 4 min read). Most of the early GLP-1 and peptide pharmacology was characterized in male-skewed cohorts. The downstream consequence is that dose interpretation in women rests on smaller samples than the labeled doses suggest. This piece covers the 1993 NIH Revitalization Act, the FDA pregnancy and lactation labeling rule, the named GLP-1 sex-stratified subgroup data, the older-research-peptide / SARM evidence gap, the menopausal-status question, and where coverage is still uneven.
• Cold exposure and recovery: what the controlled-trial data actually show, and the hypertrophy interaction (Recovery; 4 min read). Cold-water immersion has a long sports-medicine history and a more recent wellness profile. The trial data are not nothing, but they are also not what the popular framing suggests. This piece covers the named DOMS trials, the hypertrophy-blunting Roberts 2015 mechanism work, the catecholamine response, brown adipose tissue activation, the cold-shower vs full-immersion gap, the Bleakley 2012 meta-analysis, and the cardiovascular contraindications.
• Sauna and cardiovascular outcomes: cohort signals, heat-shock biology, and what the trial evidence does and does not show (Recovery; 6 min read). The Finnish KIHD cohort produced the headline sauna numbers. The randomized work fills in some of the picture but cannot answer the causal question by itself. This piece covers the named KIHD findings (Laukkanen 2015 mortality, 2017 dementia, 2018 hypertension), the acute hemodynamics, the heat-shock biology, the comparison to exercise, and the clinical contraindications.
• Compounded GLP-1 vs labeled: what the FDA says (GLP-1; 7 min read). Compounded semaglutide and tirzepatide are not generic Wegovy or Zepbound. They sit in a regulatory gap the FDA has flagged repeatedly. This covers the 503A vs 503B framework, the shortage history that opened the lane and the 2024 to 2025 closing of it, the salt-form problem, the documented dosing-error deaths, the telehealth and international channels, and what the trial data does and does not carry over.
• Tesamorelin and visceral fat: what the labeled trial evidence supports, and what it does not (Peptides; 7 min read). Tesamorelin is one of the few peptides with a clear, narrow FDA label and substantial human trial evidence for visceral fat reduction. The off-label conversation runs much wider than the label. Here's the rundown: discovery, mechanism, the pivotal phase 3 program, the NAFLD signal, the IGF-1 monitoring picture, the Egrifta WR vs Egrifta SV product history, and the doping posture.
• Wearable sleep tracking vs. polysomnography: how accurate stage detection actually is, and what your sleep score really measures (Sleep; 5 min read). Wrist wearables show you a sleep architecture chart that looks a lot like polysomnography. The validation literature is more sober: total sleep time is decent, stage detection is rough, and the score on the screen is a blended construct, not a clinical measurement. This piece covers the named evidence base (the Chinoy 2021 device validation and the de Zambotti 2019 review), what wearables actually sense, the AASM scoring standard, the Apple Watch / Whoop / Oura / Fitbit head-to-head data, the sleep-score blackbox question, and the home sleep apnea testing alternative.
• Senolytics in early human trials: what dasatinib plus quercetin and fisetin actually showed, and the senescence-marker problem (Longevity; 7 min read). Senolytic biology is genuinely exciting in animal models. The early human trials are smaller, narrower, and more cautious than the popular framing. This piece covers cellular-senescence biology, the dasatinib + quercetin (D+Q) Mayo Clinic pilot program, the Hickson IPF trial, the Justice diabetic kidney trial, the failed UBX0101 osteoarthritis program, the fisetin trials, the Sprycel (dasatinib) safety profile, and the open senescence-quantification problem.
• Rapamycin and the off-label longevity conversation: mTOR biology, the human pilots, and the dose question (Longevity; 8 min read). Rapamycin (sirolimus) is the most-discussed off-label longevity intervention in 2026. The animal evidence is robust, the human evidence is small and mostly surrogate, and the dose-and-schedule question is unresolved. This piece covers the discovery story, mTOR mechanism, the labeled indications, the ITP mouse-lifespan results, the Mannick immune-aging trials, the PEARL pilot, the off-label-prescriber landscape, and the safety surveillance gap.
• Tirzepatide vs semaglutide: what the trials show (GLP-1; 8 min read). Tirzepatide and semaglutide are the two dominant GLP-1-class drugs in 2026. There is now a direct obesity head-to-head (SURMOUNT-5) and a diabetes head-to-head (SURPASS-2), and both went to tirzepatide on weight. This walks the pharmacology, the full STEP and SURMOUNT programs, the cardiovascular data, the boxed warnings, and the compounded-vs-labeled line, then says what the comparison does and does not settle.